<code id='45047A466C'></code><style id='45047A466C'></style>
    • <acronym id='45047A466C'></acronym>
      <center id='45047A466C'><center id='45047A466C'><tfoot id='45047A466C'></tfoot></center><abbr id='45047A466C'><dir id='45047A466C'><tfoot id='45047A466C'></tfoot><noframes id='45047A466C'>

    • <optgroup id='45047A466C'><strike id='45047A466C'><sup id='45047A466C'></sup></strike><code id='45047A466C'></code></optgroup>
        1. <b id='45047A466C'><label id='45047A466C'><select id='45047A466C'><dt id='45047A466C'><span id='45047A466C'></span></dt></select></label></b><u id='45047A466C'></u>
          <i id='45047A466C'><strike id='45047A466C'><tt id='45047A466C'><pre id='45047A466C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:1
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Readout Newsletter: Beam, Prozac, "TechBio" and more
          Readout Newsletter: Beam, Prozac, "TechBio" and more

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          3 questions for the future of Biden's cancer moonshot

          PresidentJoeBidenEliseAmendola/APWASHINGTON—ThelatestphaseofPresidentBiden’sCancerMoonshotinitiative